Share on StockTwits

Vical (NASDAQ:VICL) CAO Anthony Alan Ramos sold 12,500 shares of Vical stock in a transaction dated Tuesday, August 26th. The shares were sold at an average price of $1.25, for a total transaction of $15,625.00. Following the sale, the chief accounting officer now directly owns 88,364 shares in the company, valued at approximately $110,455. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Vical (NASDAQ:VICL) traded down 0.79% during mid-day trading on Wednesday, hitting $1.26. 307,539 shares of the company’s stock traded hands. Vical has a 52-week low of $1.01 and a 52-week high of $1.79. The stock’s 50-day moving average is $1.26 and its 200-day moving average is $1.27. The company’s market cap is $111.6 million.

Vical (NASDAQ:VICL) last released its earnings data on Thursday, July 31st. The company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.05). The company had revenue of $4.50 million for the quarter, compared to the consensus estimate of $1.90 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. The company’s quarterly revenue was up 200.0% on a year-over-year basis. Analysts expect that Vical will post $-0.17 EPS for the current fiscal year.

Separately, analysts at Zacks downgraded shares of Vical from an “outperform” rating to a “neutral” rating in a research note on Wednesday, July 23rd. They now have a $1.40 price target on the stock.

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (NASDAQ:VICL) delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.